New mRNA vaccine targets common virus behind mono and cancer risks
NCT ID NCT07557602
First seen May 01, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This early-stage study tests a new mRNA vaccine called VXCO-102 in 45 healthy adults aged 18 to 25. The goal is to see if the vaccine is safe and triggers an immune response against Epstein-Barr virus, which can cause mononucleosis and is linked to certain cancers. Participants will receive either the vaccine or a placebo, and researchers will monitor for side effects and measure antibodies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
-
Q-Pharm Pty Ltd/Nucleus Network Pty Ltd
Herston, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.